NDAINJECTIONINJECTABLE
Approved
Oct 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Durabolin (nandrolone phenpropionate) is an injectable anabolic steroid approved in 1959 for therapeutic use. The product mechanism involves androgenic and anabolic activity, primarily used historically in select clinical indications. Modern use is limited due to regulatory restrictions and the legacy status of this compound.
LOE Approaching
Durabolin is a legacy product with minimal growth potential and modest commercial footprint, suggesting a small, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Durabolin offers limited career advancement; roles focus on regulatory compliance, safety monitoring, and brand maintenance rather than growth or innovation. This product is best suited for professionals seeking stable, specialized expertise in legacy pharmaceutical management.
Regulatory Affairs SpecialistCompliance Officer
Worked on DURABOLIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.